bio process.jpg
BioProcess360 Partners launch dedicated Life Sciences investment fund to grow emerging bioprocessing tools and technologies
17 juil. 2024 05h15 HE | BioProcess360
BioProcess360 Partners announce the launch of a new investment fund to support businesses with the growth of emerging bioprocessing technologies
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational
11 juil. 2024 08h00 HE | Rentschler Biopharma SE
Largest expansion in company’s 150+-year history opensMajor client project already underway; new clients actively being onboarded LAUPHEIM, Germany and MILFORD, Mass., July 11, 2024 (GLOBE...
Cellectis Logo.png
Monthly information on share capital and company voting rights
05 juil. 2024 16h30 HE | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
blue-mountain-logo-blue 1 1.png
Blue Mountain and Zifo, Global Leaders in Life Sciences Pharmaceutical Manufacturing, Announce Strategic Partnership to Revolutionize Enterprise Asset Management
27 juin 2024 09h00 HE | Blue Mountain
Blue Mountain and Zifo announce a partnership to enhance efficiency and innovation in the life sciences sector, offering advanced solutions for GMP.
Cellectis Logo.png
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
20 juin 2024 16h30 HE | Cellectis Inc.
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
NodThera_logo.jpg
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
12 juin 2024 07h00 HE | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
DMR Logo.png
Cell Therapy Market Is Expected To Reach a Revenue Of USD 32.5 Bn By 2033, At 18.6% CAGR | Dimension Market Research
10 juin 2024 12h01 HE | Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Cell Therapy Market size is expected to reach USD 7.0 billion by 2024 and is further anticipated to reach USD 32.5 billion by...
DMR Logo.png
CDMO Market Forecast USD 530.3 Billion by 2033 at 7.7% CAGR Growth Rate | Dimension Market Research
10 juin 2024 10h57 HE | Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Overview The Global CDMO Market size is expected to reach USD 272.4 billion by 2024 and is further anticipated to reach USD 530.3 billion by 2033 at a...
DMR Logo.png
Biopharmaceutical Market to Reach USD 1,829.2 Billion by 2033, Growing at 15.4% CAGR | Dimension Market Research
10 juin 2024 10h12 HE | Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Overview: The Global Biopharmaceutical Market size reached USD 436.7 billion in 2023 and is further anticipated to reach USD 1,829.2 billion by 2033...
Rhino Health to Deliver Enterprise Federated Computing Solutions in Collaboration With NVIDIA
10 juin 2024 05h00 HE | Rhino Health
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Rhino Health, the global leader in federated computing, today announced a collaboration with NVIDIA to provide an enterprise-hardened federated computing...